Gaetano Corazzelli

1.8k total citations
38 papers, 682 citations indexed

About

Gaetano Corazzelli is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Gaetano Corazzelli has authored 38 papers receiving a total of 682 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pathology and Forensic Medicine, 19 papers in Genetics and 11 papers in Oncology. Recurrent topics in Gaetano Corazzelli's work include Lymphoma Diagnosis and Treatment (29 papers), Chronic Lymphocytic Leukemia Research (14 papers) and CNS Lymphoma Diagnosis and Treatment (9 papers). Gaetano Corazzelli is often cited by papers focused on Lymphoma Diagnosis and Treatment (29 papers), Chronic Lymphocytic Leukemia Research (14 papers) and CNS Lymphoma Diagnosis and Treatment (9 papers). Gaetano Corazzelli collaborates with scholars based in Italy, Malaysia and Ukraine. Gaetano Corazzelli's co-authors include Antonio Pinto, Ferdinando Frigeri, Rosaria De Filippi, Filippo Russo, Gaetana Capobianco, Manuela Arcamone, Gianpaolo Marcacci, Caterina Stelitano, Cristina Becchimanzi and Francesco Zaja and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Gaetano Corazzelli

38 papers receiving 659 citations

Peers

Countries citing papers authored by Gaetano Corazzelli

Since Specialization

Citations

This map shows the geographic impact of Gaetano Corazzelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gaetano Corazzelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gaetano Corazzelli more than expected).

Fields of papers citing papers by Gaetano Corazzelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gaetano Corazzelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gaetano Corazzelli. The network helps show where Gaetano Corazzelli may publish in the future.

Co-authorship network of co-authors of Gaetano Corazzelli

This figure shows the co-authorship network connecting the top 25 collaborators of Gaetano Corazzelli. A scholar is included among the top collaborators of Gaetano Corazzelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gaetano Corazzelli. Gaetano Corazzelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long‐term efficacy and safety of dose‐dense and dose‐intense ABVD without consolidation radiotherapy in patients with advanced Hodgkin lymphoma: A 15‐year follow‐up of the ABVD_DD‐DI phase II study 2024 ·British Journal of Haematology ·Gaetano Corazzelli, Annarosa Cuccaro, Emanuela Morelli, Manuela Arcamone, Annarosaria De Chiara, Andrea Paccone, Antonella Petrillo, (unknown), Corrado Aversa, (unknown), Francesco Volzone, (unknown), Gaetana Capobianco, (unknown), (unknown), Stefania Crisci, Rosaria De Filippi, Antonio Pinto	1
2	Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers 2021 ·Cancers ·Raffaele Di Francia, Stefania Crisci, (unknown), Concetta Cafiero, Agnese Re, (unknown), Rosaria De Filippi, Ferdinando Frigeri, Gaetano Corazzelli, Alessandra Micera, Antonio Pinto	70
3	Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma 2018 ·British Journal of Haematology ·Domenico Galati, Serena Zanotta, Gaetano Corazzelli, Dario Bruzzese, Gaetana Capobianco, Emanuela Morelli, Manuela Arcamone, Rosaria De Filippi, Antonio Pinto	13
4	Dendritic cells in hematological malignancies 2016 ·Critical Reviews in Oncology/Hematology ·Domenico Galati, Gaetano Corazzelli, Rosaria De Filippi, Antonio Pinto	26
5	A phase 1/2 study of lenalidomide and bendamustine (LEBEN) in chemorefractory Hodgkin lymphoma. 2014 ·Journal of Clinical Oncology ·Gaetano Corazzelli, (unknown), Vincenzo Pavone, F. Angrilli, Pier Luigi Zinzani, Michele Spina, Mariapaola Fina, Stefania Crisci, Rosa Calemma, Manuela Arcamone, Emanuela Morelli, Domenico Galati, Ferdinando Frigeri, Rosaria De Filippi, Antonio Pinto	2
6	BCL10 expression and localization in ocular adnexa MALT lymphomas: a comparative cytogenetic and immunohistochemical study. 2014 ·PubMed ·Margherita Cerrone, Francesca Collina, A. Chiara, Gaetano Corazzelli, (unknown), Amalia De Renzo, Filippo Russo, Monica Cantile, Stefania Staibano, Diego Strianese, Fausto Tranfa, Gerardo Botti, Gaetano De Rosa, Renato Franco	3
7	Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma 2012 ·British Journal of Haematology ·Gaetano Corazzelli, F. Angrilli, Alfonso Maria D’Arco, Felicetto Ferrara, Pellegrino Musto, Attilio Guarini, Maria Christina Cox, Caterina Stelitano, Sergio Storti, Emilio Iannitto, (unknown), Catello Califano, Alfonso Amore, Manuela Arcamone, Rosaria De Filippi, Antonio Pinto	44
8	Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas 2011 ·European Journal Of Haematology ·Gaetano Corazzelli, Ferdinando Frigeri, Manuela Arcamone, Luigi Aloj, Gaetana Capobianco, Cristina Becchimanzi, Emanuela Morelli, Francesco Volzone, Gianpaolo Marcacci, Filippo Russo, Rosaria De Filippi, Secondo Lastoria, Antonio Pinto	1
9	RD‐CODOX‐M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B‐cell lymphoma 2011 ·British Journal of Haematology ·Gaetano Corazzelli, Ferdinando Frigeri, Filippo Russo, Chiara Frairia, Manuela Arcamone, Gennaro Esposito, Annarosaria De Chiara, Emanuela Morelli, Gaetana Capobianco, Cristina Becchimanzi, Francesco Volzone, (unknown), G. Marcacci, Rosaria De Filippi, Umberto Vitolo, Antonio Pinto	57
10	Biweekly rituximab, cyclophosphamide, vincristine, non‐pegylated liposome‐encapsulated doxorubicin and prednisone (R‐COMP‐14) in elderly patients with poor‐risk diffuse large B‐cell lymphoma and moderate to high ‘life threat’ impact cardiopathy 2011 ·British Journal of Haematology ·Gaetano Corazzelli, Ferdinando Frigeri, Manuela Arcamone, (unknown), (unknown), Emanuela Morelli, Alfonso Amore, Gaetana Capobianco, (unknown), Cristina Becchimanzi, Francesco Volzone, Gianpaolo Marcacci, Filippo Russo, Rosaria De Filippi, Lucia Mastrullo, Antonio Pinto	41
11	Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination 2011 ·The Oncologist ·Andrés J.M. Ferreri, Giada Licata, Marco Foppoli, Gaetano Corazzelli, Emanuele Zucca, Caterina Stelitano, Francesco Zaja, Sergio Fava, Rossella Paolini, Alberto Franzin, Letterio S. Politi, Maurilio Ponzoni, Michele Reni	24
12	Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial. 2010 ·Blood ·Gaetano Corazzelli, Ferdinando Frigeri, Gianpaolo Marcacci, Cristina Becchimanzi, Gaetana Capobianco, Manuela Arcamone, Emanuela Morelli, Francesco Volzone, Filippo Russo, Antonio Pinto	11
13	Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma 2009 ·Cancer Chemotherapy and Pharmacology ·Gaetano Corazzelli, Gaetana Capobianco, Manuela Arcamone, Pier Ferruccio Ballerini, Emilio Iannitto, Filippo Russo, Ferdinando Frigeri, Cristina Becchimanzi, Gianpaolo Marcacci, Annarosaria De Chiara, Antonio Pinto	58
14	Randomized phase II trial on primary chemotherapy with high-dose methotrexate (HD-MTX) alone or associated with high-dose cytarabine (HD-araC) for patients with primary CNS lymphoma (I.E.L.S.G. #20 Trial): Tolerability, activity, and survival analyses 2009 ·Journal of Clinical Oncology ·Andrés J.M. Ferreri, Michele Reni, MF Martelli, Gerassimos A. Pangalis, Maurizio Frezzato, (unknown), Alberto Fabbri, Gaetano Corazzelli, Emanuele Zucca, Franco Cavalli	1
15	Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study 2006 ·Annals of Oncology ·Gaetano Corazzelli, Filippo Russo, Giampiero Capobianco, Gianpaolo Marcacci, (unknown), Antonio Pinto	33
16	Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas. 2005 ·PubMed ·Gaetano Corazzelli, Gaetana Capobianco, Filippo Russo, Ferdinando Frigeri, Donatella Aldinucci, Antonio Pinto	19
17	Gemcitabine, Ifosfamide, Oxaliplatin and Rituximab (R-GIFOX), a New Effective Cytoreductive/Mobilizing Salvage Regimen for Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma: Results of a Pilot Study. 2005 ·Blood ·Gaetano Corazzelli, Filippo Russo, Gaetana Capobianco, Gianpaolo Marcacci, (unknown), Antonio Pinto	3
18	Aging and the hemopoietic system 2003 ·Critical Reviews in Oncology/Hematology ·Antonio Pinto, Rosaria De Filippi, Ferdinando Frigeri, Gaetano Corazzelli, Nicola Normanno	23
19	Chronic lymphocytic leukaemia and neuroendocrine cancer 1999 ·British Journal of Haematology ·(unknown), Stefano Guadagni, Gaetano Corazzelli, Ferdinando Frigeri, (unknown), G Abate	1
20	Neurologic complications of Hodgkin's disease: A case history 1997 ·Annals of Oncology ·Getahun Abate, Gaetano Corazzelli, Andrea Ciarmiello, S. Monfardini	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact